Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8271
Buy Now

Market Overview:

The 7 major seasonal influenza markets reached a value of US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 41.6 Billion by 2034, exhibiting a growth rate (CAGR) of 15.08% during 2024-2034.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 8.9 Billion
Market Forecast in 2034
US$ 41.6 Billion
Market Growth Rate 2024-2034 15.08%


The seasonal influenza market has been comprehensively analyzed in IMARC's new report titled "Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seasonal influenza, commonly referred to as flu, is a contagious respiratory disorder caused by the influenza viruses. It typically occurs in seasonal outbreaks, mainly during the fall and winter months in temperate regions. This condition spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also be transmitted by coming into contact with contaminated surfaces and then touching the mouth, nose, or eyes. The common symptoms of this ailment include fever, body aches, runny or stuffy nose, fatigue, cough, loss of appetite, weakness, diarrhea, sore throat, vomiting, nausea, chills, headaches, etc. The diagnosis of seasonal influenza typically involves a combination of a medical history review, clinical feature assessment, and laboratory procedures. During an initial exam, the healthcare provider may evaluate lung function and check for other physical indicators of respiratory illness. Additionally, rapid influenza diagnostic tests (RIDTs) are recommended to validate the presence of viral antigens in patients. Numerous molecular techniques, such as reverse transcription-polymerase chain reaction and nucleic acid amplification tests, are further utilized to obtain details about viral load and strain characterization.

The increasing cases of airborne diseases due to various factors, including cold weather, dry air, enhanced crowding in enclosed spaces, etc., are primarily driving the seasonal influenza market. In addition to this, the rising prevalence of weakened immunity that can impair the respiratory tract's natural defense mechanisms, making individuals more susceptible to viral infections, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antiviral drugs, like oseltamivir, zanamivir, peramivir, etc., to reduce the severity and duration of flu symptoms among patients is further bolstering the market growth. Apart from this, the inflating application of saline nasal spray, which works by flushing out mucus and irritants from the nasal passages to relieve congestion, minimize post-nasal drip, and alleviate sinus discomfort, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chemoprophylaxis techniques, since they can effectively reduce the risk of acquiring viral infections, thereby slowing down the spread of the disease, is expected to drive the seasonal influenza market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the seasonal influenza market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for seasonal influenza and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seasonal influenza market in any manner.

Recent Developments:

  • In April 2024, CureVac N.V. disclosed interim data from an ongoing Phase 2 part of the combined Phase 1/2 research of its seasonal influenza vaccine candidate, which is being conducted in collaboration with GSK. The multivalent candidate was chosen from a comprehensive Phase 1 trial that examined vaccination candidates with up to eight different mRNA constructions each. It was developed to provide broad antigen coverage by encoding antigens that correspond to all four WHO-recommended flu strains.


Key Highlights:

  • Seasonal influenza is an acute viral infection that affects 5-10% of adults and 20-30% of children each year.
  • Every year, over a billion instances of seasonal influenza are reported, with 3-5 million cases resulting in severe disease.
  • It causes between 290,000 and 650,000 respiratory deaths each year.
  • Developing countries account for 99 percent of mortality among children under the age of five due to influenza-related lower respiratory tract infections.
  • Annual influenza epidemics often occur in the United States during winter and the fall.


Drugs:

Tamiflu (Oseltamivir) is approved for the treatment and prevention of influenza in adults and children one year of age and above. Tamiflu is an oral neuraminidase inhibitor (NAI) that prevents the influenza virus from spreading by inhibiting its replication at certain places in the body.

mRNA-1011 is under clinical development by Moderna for the prevention of seasonal influenza, including influenza A H1N1, H3N2 and influenza B yamagata and victoria strains. It is a pentavalent vaccination that contains mRNA encoding hemagglutinin (HA) glycoproteins from five flu strains (influenza A H1N1, H3N2, and influenza B Yamagata, Victoria strains, as well as one additional HA strain).

VXA-A1.1 is an oral influenza vaccination tablet created by Vaxart, Inc. It is a replication-defective adenovirus type-5 vaccine expressing influenza hemagglutinin. VXA-A1.1 demonstrated that the vaccine was well-tolerated and offered immunity against viral shedding, exceeding the efficiency of an established intramuscular vaccination.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the seasonal influenza market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the seasonal influenza market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current seasonal influenza marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Tamiflu (Oseltamivir) Roche
Relenza (Zanamivir) Vaxart/GlaxoSmithKline
Rapivab (Peramivir) BioCryst Pharmaceuticals
Xofluza (Baloxavir marboxil) Roche/Shionogi
mRNA-1011 Moderna Therapeutics
mRNA1030 Moderna Therapeutics
mRNA 1010 Moderna Therapeutics
VXA-A1.1 Vaxart


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the seasonal influenza market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the seasonal influenza market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the seasonal influenza market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of seasonal influenza across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of seasonal influenza by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of seasonal influenza by gender across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of seasonal influenza by type across the seven major markets?
  • How many patients are diagnosed (2018-2034) with seasonal influenza across the seven major markets?
  • What is the size of the seasonal influenza patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of seasonal influenza?
  • What will be the growth rate of patients across the seven major markets?
     

Seasonal Influenza: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for seasonal influenza drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the seasonal influenza market?
  • What are the key regulatory events related to the seasonal influenza market?
  • What is the structure of clinical trial landscape by status related to the seasonal influenza market?
  • What is the structure of clinical trial landscape by phase related to the seasonal influenza market?
  • What is the structure of clinical trial landscape by route of administration related to the seasonal influenza market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More